Entering text into the input field will update the search result below

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Chetan Woodun profile picture
Chetan Woodun


  • After a long and painful downside, TFFP's stock has finally delivered a one-day outperformance with respect to the big Covid plays due to the Omicron variant.
  • The next question is whether this is just another blip as was the case in July when there were positive clinical trials results for Augmenta's drug candidate using TFF (Thin Film Freezing) delivery.
  • The answer lies in the ability to leverage existing drugs with known safety profiles and reformulate these such as Niclosamide.
  • Despite high operational expenses, finances are adequate, with the pharma sharing costs through partnerships with biotechs.
  • Still, at an early stage, the road to commercialization could be a long one, but in the meanwhile, there are opportunities to benefit through licensing of intellectual property assets.

Coronavirus B.1.1.529 - COVID-19 Variant omicron digital concept cancelled flying

Vertigo3d/E+ via Getty Images

Given the number of mutations it harbors, the new Covid variant called Omicron is potentially more contagious. What worries authorities the most is that it could evade vaccines, with preliminary data from South Africa pointing

This article was written by

Chetan Woodun profile picture
My aim is to provide differentiated insights, whether it is for investing, trading, or informational reasons. For this purpose, I am not a classical equity researcher or fund manager, but, I come from the IT world as the founder of Keylogin Information and Technologies Co. Ltd. Thus, my research is often backed by analytics and I make frequent use of charts to support my position.I also invest, and thus, in this tumultuous market, I often look for strategies to preserve capital. As per my career history below, I have wide experience, initially as an implementer in virtualization and cloud, and I was subsequently a team leader and project lead, mostly working in telcos.I like to write around themes like automated supply chains, Generative AI, telcos Capex, the deflationary nature of software, semiconductors, etc and I am often contrarian. I have also covered biotechs.I have also been an entrepreneur in real estate ( a mediocre one), a business owner, and a farmer, and dedicate at least 5 hours per week to working on a non-profit basis. For this purpose, I help needy families by providing sponsored work and contributing peer reviews and opinions for enterprise tech.I have been investing for the last 25 years, initially in mutual or indexed funds before later opting for individual stocks. Got a lot of experience in the 2008/2009 downturn when I lost a lot due mostly to wrong advice. Since then I do my own research and have fallen in love with Seeking Alpha because of the unique perspectives it provides to someone investing hard-earned money as well as access to some of the best analysts.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This is an investment thesis and is intended for informational purposes. Investors are kindly requested to do additional research before investing.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

GreenGrowthGeek profile picture
The catalysts have not been so timid in the recent 5 trading days. The share price is up 39% and there are numerous catalysts coming. The stock is still very undervalued. 2022 will see a significant revaluation of the Market Cap.
GreenGrowthGeek profile picture
Now is the time for even traders and friends and family to buy shares or options in $TFFP. Only 11 trading days left for a promised deal to come. The TFFP CEO Glenn Mates has stated that they have 45 material transfer agreements with different pharma companies and are working with "the majority of the top 20 pharma companies." He has also promised a deal or two by year's end and for the company to be "revenue positive" in 2021. The clock is running and Mattes has excellent connections in the Pharma World. He will not be left hanging with egg on his face IMO.
User 10263571 profile picture
Good article in helping investors become acquainted with TFFP and its potentially game - changing technology platform in the bio - pharmacy space. That said, in some ways, the article just scratches the surface on the TFFP opportunity.

In addition to its internal programs (two of which will generate interim phase II clinical data by mid 2022), they are working an extraordinary number of collaborations with academia, government and large pharmacy companies.

They have signed several dozen Material Transfer Agreements (MTA's) with the pharmacy companies and, according to the company, are in advanced negotiation on deals for some of these.

The company has more irons in the fire than any other small cap biotech company I can find. The many shots on goal have an excellent chance to develop into revenues and a rerating in the stock.

I would suggest listening to the company's conference presentations and quarterly calls and visiting their website for further information.
GreenGrowthGeek profile picture
@User 10263571 "the article just scratches the surface on the TFFP opportunity." Spot on.

"The company has more irons in the fire than any other small cap biotech company I can find. The many shots on goal have an excellent chance to develop into revenues and a rerating in the stock." Double Spot On

There are many biotech/pharma investors who will be asking themselves within a couple months "how did I miss this one?"
In many ways $TFFP is not a traditional small biotech company as it's truly a Revolutionary/Market Disruptor in Drug Delivery Technology. It has way more shots on goal than any small company I know in any sector.
GreenGrowthGeek profile picture
PHD Roth analyst reiterated his Buy of TFFP today citing Pandemic drivers and other catalyst. His Price Target is $27
Here's a small portion of his thesis:

TFFP: Numerous Opportunities Not Reflected In Current Market Valuation

With the emergence of the omicron variant that could potentially thwart commercial and clinical-stage vaccine and direct antiviral products, we are reminded that SARS-CoV-2 is highly unlikely to go away or to be mutationally constrained in any significant way. We therefore emphasize several of TFFP's clinical and preclinical development programs for vaccines and drugs intended to combat SARS-CoV-2 in ways that address specific real issues with current vaccines and drugs. We still expect TFFP to sign a transformational deal near-term.
We note the swiftness of the World Health Organization to designate the highly transmissible omicron variant as a variant of concern, and omicron's emergence in parts of Africa with particularly low vaccination rates. As African countries accelerate the deployment of COVID-19 vaccines, the issue of vaccine hesitancy looms, an issue that is clearly not specific to African countries. Vaccination rates in Africa are dually impacted by a substantial vaccine shortage as well as vaccine hesitancy, with the limited vaccine supply there resulting from structural issues and logistical barriers. Should omicron establish itself in the U.S., increased indoor gatherings promoted by the coming winter season would be expected to result in spikes in infections, hospitalizations, and deaths. We also note Merck's (MRK-NC) news last week that its final molnupiravir trial data revealed a 30% reduction in hospitalization versus the interim data's indication of a 50% reduction in hospitalization.
Given that viral evolution is inescapable, we believe that TFFP can offer three differentiated solutions, an inhalable niclosamide targeting cellular pathways of cells infected with RNA viruses, inhalable (or easily reconstituted) vaccines that obviate the need for cold chain continuity, a feature that would be especially useful in underdeveloped countries. TFFP's collaboration with Augmenta Bioworks, although focused on relatively costly mAb technology, could potentially free such a product from cold chain constraints. We view TFFP as being well-positioned to generate differentiated products against COVID-19 that fit with the various logistical barriers of many countries.
Inhalable niclosamide is in Phase 1 in collaboration with partner UNION Therapeutics, and is not a direct antiviral, allowing it to likely remain effective as SARS-CoV-2 mutates. We expect TFFP to complete Phase 1 dosing in early 2022, allowing the company to pursue initial efficacy trials in COVID patients immediately thereafter. We note that inhaled dry powder niclosamide efficiently enters the alveoli and that about 50% of the inhaled dose can enter systemic circulation, versus less than 10% of niclosamide becoming systemic after standard oral dosing, but that the inhaled dose is much lower than the oral dose and thus we do not view this systemic circulation as a likely safety issue (Cmax of an inhaled dose is about twice that for a high oral dose).
GreenGrowthGeek profile picture
If what $TFFP management states is true that the TFF tech can transform any vaccine, mAb or other drug/compound into a dry powder that captures a high level of the active compound, has excellent shelf life, can be delivered either through the nose or mouth with up to 85% penetration into the deep lung and thereby at lower doses to mitigate side effects then the TFF platform will truly be a game changer in the War against Covid and for many other lung diseases for that matter. The dry powder can be reformulated on site in remote and hot/humid areas of the world to inject as a vaccine OR it could be inhaled. This would be huge in getting vaccines into African countries, India, the Philippines and many other places.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.